{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:49Z","timestamp":1787169769697,"version":"build-2736575974"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by the National Natural Science Foundation of China","award":["81974258"],"award-info":[{"award-number":["81974258"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The cross talk between immune and non-immune cells in the tumor microenvironment leads to immunosuppression, which promotes tumor growth and survival. Immunotherapy is an advanced treatment that boosts humoral and cellular immunity rather than using chemotherapy or radiation-based strategy associated with non-specific targets and toxic effects on normal cells. Immune checkpoint inhibitors and T cell-based immunotherapy have already exhibited significant effects against solid tumors and leukemia. Tumor cells that escape immune surveillance create a major obstacle to acquiring an effective immune response in cancer patients. Tremendous progress had been made in recent years on a wide range of innate and adaptive immune checkpoints which play a significant role to prevent tumorigenesis, and might therefore be potential targets to suppress tumor cells growth. This review aimed to summarize the underlying molecular mechanisms of existing immunotherapy approaches including T cell and NK-derived immune checkpoint therapy, as well as other intrinsic and phagocytosis checkpoints. Together, these insights will pave the way for new innate and adaptive immunomodulatory targets for the development of highly effective new therapy in the future.<\/jats:p>","DOI":"10.1007\/s10238-022-00887-0","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T15:03:26Z","timestamp":1663254206000},"page":"553-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The new progress in cancer immunotherapy"],"prefix":"10.1007","volume":"23","author":[{"given":"Ajmeri Sultana","family":"Shimu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-xing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xucai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"issue":"1","key":"887_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","volume":"16","author":"TL Whiteside","year":"2006","unstructured":"Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16(1):3\u201315.","journal-title":"Semin Cancer Biol"},{"key":"887_CR2","doi-asserted-by":"crossref","unstructured":"Harris, T. J.; Drake, C. G., Primer on tumor immunology and cancer immunotherapy. J Immuno Therapy Cancer 2013, 1.","DOI":"10.1186\/2051-1426-1-12"},{"key":"887_CR3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biopha.2015.10.020","volume":"76","author":"VI Seledtsov","year":"2015","unstructured":"Seledtsov VI, Goncharov AG, Seledtsova GV. Multiple-purpose immunotherapy for cancer. Biomed Pharmacother. 2015;76:24\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"887_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1039\/C0IB00046A","volume":"3","author":"T Tian","year":"2011","unstructured":"Tian T, Olson S, Whitacre JM, Harding A. The origins of cancer robustness and evolvability. Integr Biol. 2011;3(1):17\u201330.","journal-title":"Integr Biol"},{"issue":"4","key":"887_CR5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"887_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"issue":"8","key":"887_CR7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","volume":"13","author":"MH Kershaw","year":"2013","unstructured":"Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013;13(8):525\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"887_CR8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u20138.","journal-title":"Nat Immunol"},{"issue":"9","key":"887_CR9","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1172\/JCI80004","volume":"125","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Investig. 2015;125(9):3338\u201346.","journal-title":"J Clin Investig"},{"issue":"2","key":"887_CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/22123938MTE1oMDQm5","volume":"17","author":"W Zam","year":"2021","unstructured":"Zam W, Ali L. Immune checkpoint inhibitors in the treatment of cancer. Curr Rev Clin Exp Pharmacol. 2021;17(2):103\u201313.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"887_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.08.007","volume":"95","author":"P Kumar","year":"2018","unstructured":"Kumar P, Bhattacharya P, Prabhakar BS. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun. 2018;95:77\u201399.","journal-title":"J Autoimmun"},{"issue":"1","key":"887_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","volume":"27","author":"H Nishikawa","year":"2014","unstructured":"Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27(1):1\u20137.","journal-title":"Curr Opin Immunol"},{"key":"887_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44\u201351.","journal-title":"Curr Opin Immunol"},{"key":"887_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","volume":"65","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65:13\u201327.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"887_CR15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","volume":"117","author":"A Taylor","year":"2006","unstructured":"Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-$$: The role of T regulatory cells. Immunology. 2006;117(4):433\u201342.","journal-title":"Immunology"},{"key":"887_CR16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2014.00070","volume":"4","author":"T Voron","year":"2014","unstructured":"Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J, Terme M. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70.","journal-title":"Front Oncol"},{"issue":"3","key":"887_CR17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/biomedicines10030609","volume":"10","author":"A Lerner","year":"2022","unstructured":"Lerner A, Benzvi C. Checkpoint inhibitors and induction of celiac disease-like condition. Biomedicines. 2022;10(3):609.","journal-title":"Biomedicines"},{"issue":"7528","key":"887_CR18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558\u201362.","journal-title":"Nature"},{"key":"887_CR19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"issue":"8","key":"887_CR20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","volume":"28","author":"Y Takeuchi","year":"2016","unstructured":"Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28(8):401\u20139.","journal-title":"Int Immunol"},{"issue":"10","key":"887_CR21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nri.2016.80","volume":"16","author":"DE Speiser","year":"2016","unstructured":"Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16(10):599\u2013611.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"887_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2019.11.010","volume":"225","author":"N Taefehshokr","year":"2020","unstructured":"Taefehshokr N, Baradaran B, Baghbanzadeh A, Taefehshokr S. Promising approaches in cancer immunotherapy. Immunobiology. 2020;225(2): 151875.","journal-title":"Immunobiology"},{"issue":"6","key":"887_CR23","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1002\/jcp.27816","volume":"234","author":"S Sadreddini","year":"2019","unstructured":"Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, Aghebati-Maleki L. Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol. 2019;234(6):8541\u20139.","journal-title":"J Cell Physiol"},{"issue":"6","key":"887_CR24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","volume":"31","author":"G Abril-Rodriguez","year":"2017","unstructured":"Abril-Rodriguez G, Ribas A. SnapShot: immune checkpoint inhibitors. Cancer Cell. 2017;31(6):848-848.e1.","journal-title":"Cancer Cell"},{"issue":"10","key":"887_CR25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19(10):568\u201386.","journal-title":"Nat Rev Cancer"},{"key":"887_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2019.01.006","volume":"64","author":"P Kumar","year":"2020","unstructured":"Kumar P, Saini S, Prabhakar BS. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Semin Cancer Biol. 2020;64:29\u201335.","journal-title":"Semin Cancer Biol"},{"issue":"6127","key":"887_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"JF Brunet","year":"1988","unstructured":"Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily-CTLA-4. Nature. 1988;328(6127):267\u201370.","journal-title":"Nature"},{"key":"887_CR28","doi-asserted-by":"crossref","unstructured":"Yan, Q.; Zhang, B.; Ling, X.; Zhu, B.; Mei, S.; Yang, H.; Zhang, D.; Huo, J.; Zhao, Z., CTLA-4 facilitates DNA damage\u2013induced apoptosis by interacting with PP2A. Front Cell Dev Biol 2022, 10.","DOI":"10.3389\/fcell.2022.728771"},{"issue":"6","key":"887_CR29","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.179.6.3831","volume":"179","author":"HM Gibson","year":"2007","unstructured":"Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, Tsokos GC, Wong HK. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol. 2007;179(6):3831\u201340.","journal-title":"J Immunol"},{"issue":"3","key":"887_CR30","first-page":"981","volume":"198","author":"S Hori","year":"2017","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. J Immunol. 2017;198(3):981\u20135.","journal-title":"J Immunol"},{"issue":"1","key":"887_CR31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. Am J Clin Oncol Cancer Clin Trials. 2016;39(1):98\u2013106.","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"issue":"21","key":"887_CR32","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543\u201353.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"887_CR33","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","volume":"183","author":"MF Krummel","year":"1996","unstructured":"Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183(6):2533\u201340.","journal-title":"J Exp Med"},{"issue":"5","key":"887_CR34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","volume":"44","author":"FA Schildberg","year":"2016","unstructured":"Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity. 2016;44(5):955\u201372.","journal-title":"Immunity"},{"issue":"2","key":"887_CR35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","volume":"17","author":"AV Collins","year":"2002","unstructured":"Collins AV, Brodie DW, Gilbert RJC, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, Van Der Merwe PA, Davis SJ. The interaction properties of costimulatory molecules revisited. Immunity. 2002;17(2):201\u201310.","journal-title":"Immunity"},{"issue":"5","key":"887_CR36","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebb C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522\u201330.","journal-title":"Lancet Oncol"},{"issue":"1","key":"887_CR37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: A moving target in immunotherapy. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"issue":"4","key":"887_CR38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883\u201395.","journal-title":"J Exp Med"},{"issue":"3","key":"887_CR39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","volume":"75","author":"J Li","year":"2015","unstructured":"Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL. PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of t cells in the tumor microenvironment. Can Res. 2015;75(3):508\u201318.","journal-title":"Can Res"},{"issue":"2","key":"887_CR40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.molimm.2015.02.009","volume":"67","author":"A Swaika","year":"2015","unstructured":"Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015;67(2):4\u201317.","journal-title":"Mol Immunol"},{"issue":"1","key":"887_CR41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"887_CR42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.immuni.2016.07.017","volume":"45","author":"DS Karunarathne","year":"2016","unstructured":"Karunarathne DS, Horne-Debets JM, Huang JX, Faleiro R, Leow CY, Amante F, Watkins TS, Miles JJ, Dwyer PJ, Stacey KJ, Yarski M, Poh CM, Lee JS, Cooper MA, Rnia L, Richard D, McCarthy JS, Sharpe AH, Wykes MN. Programmed death-1 ligand 2-mediated regulation of the PD-L1 to PD-1 axis Is essential for establishing CD4+ T cell immunity. Immunity. 2016;45(2):333\u201345.","journal-title":"Immunity"},{"issue":"13","key":"887_CR43","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015\u201329.","journal-title":"J Exp Med"},{"issue":"7235","key":"887_CR44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","volume":"458","author":"V Velu","year":"2009","unstructured":"Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ, Ahmed R, Amara RR. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458(7235):206\u201310.","journal-title":"Nature"},{"issue":"7652","key":"887_CR45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D\u2019Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60\u20135.","journal-title":"Nature"},{"issue":"7693","key":"887_CR46","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Caellas A, Hernando-Momblona X. TGF$$ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538\u201343.","journal-title":"Nature"},{"key":"887_CR47","doi-asserted-by":"crossref","unstructured":"Yi, M.; Zheng, X.; Niu, M.; Zhu, S.; Ge, H.; Wu, K., Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Molecular Cancer 2022, 21 (1).","DOI":"10.1186\/s12943-021-01489-2"},{"issue":"7637","key":"887_CR48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"5","key":"887_CR49","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0959-440X(02)00375-5","volume":"12","author":"PR Crocker","year":"2002","unstructured":"Crocker PR. Siglecs: Sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr Opin Struct Biol. 2002;12(5):609\u201315.","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"887_CR50","doi-asserted-by":"crossref","first-page":"1R","DOI":"10.1093\/glycob\/cwj008","volume":"16","author":"A Varki","year":"2006","unstructured":"Varki A, Angata T. Siglecs - The major subfamily of I-type lectins. Glycobiology. 2006;16(1):1R-27R.","journal-title":"Glycobiology"},{"issue":"4","key":"887_CR51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","volume":"7","author":"PR Crocker","year":"2007","unstructured":"Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7(4):255\u201366.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"887_CR52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","volume":"77","author":"H Lubli","year":"2020","unstructured":"Lubli H, Varki A. Sialic acid\u2013binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. Cell Mol Life Sci. 2020;77(4):593\u2013605.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"887_CR53","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1096\/fj.13-241497","volume":"28","author":"V Padler-Karavani","year":"2014","unstructured":"Padler-Karavani V, Hurtado-Ziola N, Chang YC, Sonnenburg JL, Ronaghy A, Yu H, Verhagen A, Nizet V, Chen X, Varki N, Varki A, Angata T. Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates. FASEB J. 2014;28(3):1280\u201393.","journal-title":"FASEB J"},{"issue":"6","key":"887_CR54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.15252\/embj.201695581","volume":"36","author":"F Schwarz","year":"2017","unstructured":"Schwarz F, Landig CS, Siddiqui S, Secundino I, Olson J, Varki N, Nizet V, Varki A. Paired siglec receptors generate opposite inflammatory responses to a human-specific pathogen. EMBO J. 2017;36(6):751\u201360.","journal-title":"EMBO J"},{"issue":"3","key":"887_CR55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaci.2015.01.004","volume":"135","author":"Y Jia","year":"2015","unstructured":"Jia Y, Yu H, Fernandes SM, Wei Y, Gonzalez-Gil A, Motari MG, Vajn K, Stevens WW, Peters AT, Bochner BS, Kern RC, Schleimer RP, Schnaar RL. Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells. J Allergy Clin Immunol. 2015;135(3):799-810.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"887_CR56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ni.3552","volume":"17","author":"R Beatson","year":"2016","unstructured":"Beatson R, Tajadura-Ortega V, Achkova D, Picco G, Tsourouktsoglou TD, Klausing S, Hillier M, Maher J, Noll T, Crocker PR, Taylor-Papadimitriou J, Burchell JM. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17(11):1273\u201381.","journal-title":"Nat Immunol"},{"issue":"39","key":"887_CR57","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.1409580111","volume":"111","author":"H Lubli","year":"2014","unstructured":"Lubli H, Pearce OMT, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, Deng L, Verhagen A, Secrest P, Lusk C, Schwartz AG, Varki NM, Bui JD, Varki A. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci USA. 2014;111(39):14211\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"887_CR58","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.18632\/oncotarget.6822","volume":"7","author":"M Perdicchio","year":"2016","unstructured":"Perdicchio M, Cornelissen LAM, Streng-Ouwehand I, Engels S, Verstege MI, Boon L, Geerts D, van Kooyk Y, Unger WWJ. Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells. Oncotarget. 2016;7(8):8771\u201382.","journal-title":"Oncotarget"},{"issue":"13","key":"887_CR59","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1158\/0008-5472.CAN-17-3376","volume":"78","author":"C Bull","year":"2018","unstructured":"Bull C, Boltje TJ, Balneger N, Weischer SM, Wassink M, van Gemst JJ, Bloemendal VR, Boon L, van der Vlag J, Heise T, den Brok MH, Adema GJ. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity. Cancer Res. 2018;78(13):3574\u201388.","journal-title":"Cancer Res"},{"issue":"11","key":"887_CR60","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1172\/JCI120612","volume":"128","author":"MA Stanczak","year":"2018","unstructured":"Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, Von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, Von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Lubli H. Self-associated molecular patterns mediate cancer immune evasion by engaging siglecs on T cells. J Clin Investig. 2018;128(11):4912\u201323.","journal-title":"J Clin Investig"},{"issue":"4","key":"887_CR61","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1172\/JCI65899","volume":"124","author":"C Jandus","year":"2014","unstructured":"Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Dmoulins T, Schneider C, Wehrli M, Hunger RE, Baerlocher GM, Simon HU, Romero P, Mnz C, Von Gunten S. Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Investig. 2014;124(4):1810\u201320.","journal-title":"J Clin Investig"},{"issue":"9","key":"887_CR62","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/glycob\/cwu068","volume":"24","author":"GY Chen","year":"2014","unstructured":"Chen GY, Brown NK, Zheng P, Liu Y. Siglec-G\/10 in self-nonself discrimination of innate and adaptive immunity. Glycobiology. 2014;24(9):800\u20136.","journal-title":"Glycobiology"},{"issue":"7769","key":"887_CR63","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. CD24 signalling through macrophage siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392\u20136.","journal-title":"Nature"},{"issue":"5922","key":"887_CR64","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1126\/science.1168988","volume":"323","author":"GY Chen","year":"2009","unstructured":"Chen GY, Tang J, Zheng P, Liu Y. CD24 and siglec-10 selectively repress tissue damage - Induced immune responses. Science. 2009;323(5922):1722\u20135.","journal-title":"Science"},{"issue":"5","key":"887_CR65","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nbt.1846","volume":"29","author":"GY Chen","year":"2011","unstructured":"Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Cao H, Yu H, Qu J, Fang D, Wu W, Bai XF, Liu JQ, Woodiga SA, Chen C, Sun L, Hogaboam CM, Kunkel SL, Zheng P, Liu Y. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol. 2011;29(5):428\u201335.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"887_CR66","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2013.01.011","volume":"152","author":"W Chen","year":"2013","unstructured":"Chen W, Han C, Xie B, Hu X, Yu Q, Shi L, Wang Q, Li D, Wang J, Zheng P, Liu Y, Cao X. Induction of siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell. 2013;152(3):467\u201378.","journal-title":"Cell"},{"issue":"22","key":"887_CR67","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2013-12-545335","volume":"123","author":"T Toubai","year":"2014","unstructured":"Toubai T, Hou G, Mathewson N, Liu C, Wang Y, Oravecz-Wilson K, Cummings E, Rossi C, Evers R, Sun Y, Wu J, Choi SW, Fang D, Zheng P, Liu Y, Reddy P. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood. 2014;123(22):3512\u201323.","journal-title":"Blood"},{"issue":"3","key":"887_CR68","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1189\/jlb.2MR0317-105R","volume":"102","author":"CL Abram","year":"2017","unstructured":"Abram CL, Lowell CA. Shp1 function in myeloid cells. J Leukoc Biol. 2017;102(3):657\u201375.","journal-title":"J Leukoc Biol"},{"issue":"8","key":"887_CR69","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/glycob\/cwm049","volume":"17","author":"T Angata","year":"2007","unstructured":"Angata T, Tabuchi Y, Nakamura K, Nakamura M. Siglec-15: an immune system siglec conserved throughout vertebrate evolution. Glycobiology. 2007;17(8):838\u201346.","journal-title":"Glycobiology"},{"issue":"8","key":"887_CR70","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Cells E, Chen L. Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800.","journal-title":"Nat Med"},{"key":"887_CR71","doi-asserted-by":"crossref","unstructured":"Weiping, Z.; Jedd D., W.; Lieping, C., PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: MEchanisms, Response Biomarkers and Combinations. Science Translational Medicine 2016, 8 (328).","DOI":"10.1126\/scitranslmed.aad7118"},{"issue":"10","key":"887_CR72","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014\u201322.","journal-title":"Nat Immunol"},{"issue":"8","key":"887_CR73","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.it.2018.05.001","volume":"39","author":"TK Kim","year":"2018","unstructured":"Kim TK, Herbst RS, Chen L. Defining and understanding adaptive resistance in cancer immunotherapy. Trends Immunol. 2018;39(8):624\u201331.","journal-title":"Trends Immunol"},{"issue":"1","key":"887_CR74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol. 2014;27(1):16\u201325.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"887_CR75","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313\u201326.","journal-title":"Cell"},{"issue":"3","key":"887_CR76","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbrc.2011.05.015","volume":"409","author":"Y Hiruma","year":"2011","unstructured":"Hiruma Y, Hirai T, Tsuda E. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation. Biochem Biophys Res Commun. 2011;409(3):424\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"887_CR77","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","volume":"2","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Chen L. Classification of advanced human cancers based on tumor immunity in the MicroEnvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2(11):1403\u20134.","journal-title":"JAMA Oncol"},{"issue":"4","key":"887_CR78","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O\u2019Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656\u201366.","journal-title":"Nat Med"},{"key":"887_CR79","first-page":"268","volume":"8","author":"X Chen","year":"2022","unstructured":"Chen X, Mo S, Zhang Y, Ma H, Lu Z, Yu S, Chen J. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. J Pathol: Clin Res. 2022;8:268\u201378.","journal-title":"J Pathol: Clin Res"},{"issue":"10","key":"887_CR80","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1074\/jbc.M113.494542","volume":"289","author":"M Stuible","year":"2014","unstructured":"Stuible M, Moraitis A, Fortin A, Saragosa S, Kalbakji A, Filion M, Tremblay GB. Mechanism and function of monoclonal antibodies targeting Siglec-15 for therapeutic inhibition of osteoclastic bone resorption. J Biol Chem. 2014;289(10):6498\u2013512.","journal-title":"J Biol Chem"},{"issue":"2","key":"887_CR81","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286\u201399.","journal-title":"Cell"},{"issue":"1","key":"887_CR82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRP$$ signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145\u201364.","journal-title":"Immunol Rev"},{"issue":"45","key":"887_CR83","doi-asserted-by":"crossref","first-page":"18342","DOI":"10.1073\/pnas.1106550108","volume":"108","author":"XW Zhao","year":"2011","unstructured":"Zhao XW, Van Beek EM, Schornagel K, Van Der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, Birnbaum D, Van Elsas A, Kuijpers TW, Bertucci F, Van Den Berg TK. CD47-signal regulatory protein-$$(SIRP)$$ interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA. 2011;108(45):18342\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"887_CR84","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf K. Cancer immunotherapy targeting the CD47\/SIRP$$ axis. Eur J Cancer. 2017;76:100\u20139.","journal-title":"Eur J Cancer"},{"issue":"2","key":"887_CR85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 Is Upregulated on circulating hematopoietic stem cells and Leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271\u201385.","journal-title":"Cell"},{"key":"887_CR86","doi-asserted-by":"crossref","unstructured":"Willingham, S. B.; Volkmer, J. P.; Gentles, A. J.; Sahoo, D.; Dalerba, P.; Mitra, S. S.; Wang, J.; Contreras-Trujillo, H.; Martin, R.; Cohen, J. D.; Lovelace, P.; Scheeren, F. A.; Chao, M. P.; Weiskopf, K.; Tang, C.; Volkmer, A. K.; Naik, T. J.; Storm, T. A.; Mosley, A. R.; Edris, B.; Schmid, S. M.; Sun, C. K.; Chua, M. S.; Murillo, O.; Rajendran, P.; Cha, A. C.; Chin, R. K.; Kim, D.; Adorno, M.; Raveh, T.; Tseng, D.; Jaiswal, S.; Enger, P. y.; Steinberg, G. K.; Li, G.; So, S. K.; Majeti, R.; Harsh, G. R.; Van Rijn, M. D.; Teng, N. N. H.; Sunwoo, J. B.; Alizadeh, A. A.; Clarke, M. F.; Weissman, I. L., The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America 2012; 109 (17), 6662\u20136667.","DOI":"10.1073\/pnas.1121623109"},{"key":"887_CR87","doi-asserted-by":"crossref","first-page":"114047","DOI":"10.1016\/j.ejmech.2021.114047","volume":"229","author":"Y Tan","year":"2022","unstructured":"Tan Y, Chen H, Zhang J, Cai L, Jin S, Song D, Yang T, Guo Z, Wang X. Platinum(IV) complexes as inhibitors of CD47-SIRP$$ axis for chemoimmunotherapy of cancer. Eur J Med Chem. 2022;229:114047.","journal-title":"Eur J Med Chem"},{"issue":"18","key":"887_CR88","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer J-P, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM. CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin\u2019s lymphoma. N Engl J Med. 2018;379(18):1711\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"887_CR89","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma. Cell. 2010;142(5):699\u2013713.","journal-title":"Cell"},{"issue":"49","key":"887_CR90","first-page":"E10578","volume":"114","author":"NG Ring","year":"2017","unstructured":"Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, Lietzenmayer M, McKenna KM, Naik TJ, McCarty A, Zheng Y, Ring AM, Flavell RA, Weissman IL. Anti-SIRP$$ antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci USA. 2017;114(49):E10578\u201385.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"37","key":"887_CR91","doi-asserted-by":"crossref","first-page":"13117","DOI":"10.1073\/pnas.0504184102","volume":"102","author":"KF Huang","year":"2005","unstructured":"Huang KF, Liu YL, Cheng WJ, Ko TP, Wang AHJ. Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. Proc Natl Acad Sci USA. 2005;102(37):13117\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"887_CR92","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41591-019-0356-z","volume":"25","author":"MEW Logtenberg","year":"2019","unstructured":"Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, Matlung HL, Fauster A, Gomez-Eerland R, Bakker NAM, van der Schot S, Marijt KA, Verdoes M, Haanen JBAG, van den Berg JH, Neefjes J, van den Berg TK, Brummelkamp TR, Leusen JHW, Scheeren FA, Schumacher TN. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP$$ axis and a target for cancer immunotherapy. Nat Med. 2019;25(4):612\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"887_CR93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","volume":"26","author":"RJ Kishton","year":"2017","unstructured":"Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 2017;26(1):94\u2013109.","journal-title":"Cell Metab"},{"issue":"4","key":"887_CR94","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017;168(4):724\u201340.","journal-title":"Cell"},{"issue":"4","key":"887_CR95","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998-1013.e20.","journal-title":"Cell"},{"issue":"7242","key":"887_CR96","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nature07924","volume":"458","author":"K Matsushita","year":"2009","unstructured":"Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T, Miyake T, Satoh T, Kato H, Tsujimura T, Nakamura H, Akira S. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature. 2009;458(7242):1185\u201390.","journal-title":"Nature"},{"issue":"5","key":"887_CR97","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2013.04.034","volume":"153","author":"T Uehata","year":"2013","unstructured":"Uehata T, Iwasaki H, Vandenbon A, Matsushita K, Hernandez-Cuellar E, Kuniyoshi K, Satoh T, Mino T, Suzuki Y, Standley DM, Tsujimura T, Rakugi H, Isaka Y, Takeuchi O, Akira S. XMalt1-induced cleavage of regnase-1 in CD4+ helper T cells regulates immune activation. Cell. 2013;153(5):1036.","journal-title":"Cell"},{"issue":"5","key":"887_CR98","doi-asserted-by":"crossref","first-page":"20200971","DOI":"10.1084\/jem.20200971","volume":"218","author":"N Bhat","year":"2021","unstructured":"Bhat N, Virgen-Slane R, Ramezani-Rad P, Leung CR, Chen C, Balsells D, Shukla A, Kao E, Apgar JR, Fu M, Ware CF, Rickert RC. Regnase-1 is essential for B cell homeostasis to prevent immunopathology. J Exp Med. 2021;218(5):20200971.","journal-title":"J Exp Med"},{"issue":"7","key":"887_CR99","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","volume":"175","author":"E Shifrut","year":"2018","unstructured":"Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, Li PJ, Diolaiti ME, Ashworth A, Marson A. Genome-wide CRISPR screens in primary human T Cells reveal key regulators of immune function. Cell. 2018;175(7):1958-1971.e15.","journal-title":"Cell"},{"issue":"7787","key":"887_CR100","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei J, Long L, Zheng W, Dhungana Y, Lim SA, Guy C, Wang Y, Wang YD, Qian C, Xu B, Kc A, Saravia J, Huang H, Yu J, Doench JG, Geiger TL, Chi H. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576(7787):471\u20136.","journal-title":"Nature"},{"issue":"4","key":"887_CR101","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"887_CR102","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336.","journal-title":"Nat Immunol"},{"issue":"3","key":"887_CR103","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41590-019-0577-9","volume":"21","author":"D Lu","year":"2020","unstructured":"Lu D, Liu L, Sun Y, Song J, Yin Q, Zhang G, Qi F, Hu Z, Yang Z, Zhou Z, Hu Y, Zhang L, Ji J, Zhao X, Jin Y, McNutt MA, Yin Y. The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity. Nat Immunol. 2020;21(3):287\u201397.","journal-title":"Nat Immunol"},{"issue":"8","key":"887_CR104","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561\u201384.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"887_CR105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.chom.2012.05.003","volume":"11","author":"Y Wang","year":"2012","unstructured":"Wang Y, Swiecki M, Cella M, Alber G, Schreiber RD, Gilfillan S, Colonna M. Timing and magnitude of type i interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe. 2012;11(6):631\u201342.","journal-title":"Cell Host Microbe"},{"issue":"6","key":"887_CR106","doi-asserted-by":"crossref","first-page":"eaai8593","DOI":"10.1126\/sciimmunol.aai8593","volume":"1","author":"T Wu","year":"2016","unstructured":"Wu T, Moseman EA, Xu HC, Manglani M, Kirby M, Anderson SM, Handon R, Kenyon E, Elkahloun A, Wu W, Lang PA, McGavern DB, Schwartzberg PL. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci immunol. 2016;1(6):eaai8593.","journal-title":"Sci immunol"},{"issue":"4","key":"887_CR107","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.immuni.2018.03.018","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, Lee Y, Li Y, Jiang Y, Lu H, Zang W, Zhao X, Liu L, Chen Y, Tan H, Yang Z, Zhang MQ, Mak TW, Ni L, Dong C. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells. Immunity. 2018;48(4):773-786.e5.","journal-title":"Immunity"},{"issue":"37","key":"887_CR108","doi-asserted-by":"crossref","first-page":"38228","DOI":"10.1074\/jbc.M405932200","volume":"279","author":"DW Waggoner","year":"2004","unstructured":"Waggoner DW, Johnson LB, Mann PC, Morris V, Guastella J, Bajjalieh SM. MuLK, a eukaryotic multi-substrate lipid kinase. J Biol Chem. 2004;279(37):38228\u201335.","journal-title":"J Biol Chem"},{"issue":"5","key":"887_CR109","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200407123","volume":"169","author":"M Bektas","year":"2005","unstructured":"Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol. 2005;169(5):801\u201311.","journal-title":"J Cell Biol"},{"key":"887_CR110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","volume":"30","author":"JD Powell","year":"2012","unstructured":"Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39\u201368.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"887_CR111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/ni.3082","volume":"16","author":"JP Ray","year":"2015","unstructured":"Ray JP, Craft J. PTENtiating autoimmunity through Treg cell deregulation. Nat Immunol. 2015;16(2):139\u201340.","journal-title":"Nat Immunol"},{"key":"887_CR112","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","volume":"36","author":"RIK Geltink","year":"2018","unstructured":"Geltink RIK, Kyle RL, Pearce EL. Unraveling the complex interplay between T cell metabolism and function. Annu Rev Immunol. 2018;36:461\u201388.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"887_CR113","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cmet.2019.05.016","volume":"30","author":"Z Hu","year":"2019","unstructured":"Hu Z, Qu G, Yu X, Jiang H, Teng XL, Ding L, Hu Q, Guo X, Zhou Y, Wang F, Li HB, Chen L, Jiang J, Su B, Liu J, Zou Q. Acylglycerol Kinase maintains metabolic state and immune responses of CD8+ T Cells. Cell Metab. 2019;30(2):290-302.e5.","journal-title":"Cell Metab"},{"key":"887_CR114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.smim.2017.08.003","volume":"31","author":"L Chiossone","year":"2017","unstructured":"Chiossone L, Vienne M, Kerdiles YM, Vivier E. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. Semin Immunol. 2017;31:55\u201363.","journal-title":"Semin Immunol"},{"key":"887_CR115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225\u201374.","journal-title":"Annu Rev Immunol"},{"issue":"6230","key":"887_CR116","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361.","journal-title":"Science"},{"issue":"2","key":"887_CR117","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.it.2018.12.003","volume":"40","author":"F Souza-Fonseca-Guimaraes","year":"2019","unstructured":"Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in cancer immunotherapy. Trends Immunol. 2019;40(2):142\u201358.","journal-title":"Trends Immunol"},{"issue":"9","key":"887_CR118","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/cmi.2017.2","volume":"15","author":"IT Chyuan","year":"2018","unstructured":"Chyuan IT, Tsai HF, Liao HJ, Wu CS, Hsu PN. An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis. Cell Mol Immunol. 2018;15(9):846\u201357.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"887_CR119","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503\u201310.","journal-title":"Nat Immunol"},{"key":"887_CR120","first-page":"10","volume":"2019","author":"J Bi","year":"1999","unstructured":"Bi J, Tian Z. NK cell dysfunction and checkpoint immunotherapy. Front Immunol. 1999;2019:10.","journal-title":"Front Immunol"},{"key":"887_CR121","doi-asserted-by":"crossref","unstructured":"Smyth, M. J.; Thia, K. Y.; Cretney, E.; Kelly, J. M.; Snook, M. B.; Forbes, C. A.; Scalzo, A. A., Perforin is a major contributor to NK cell control of tumor metastasis. Journal of immunology (Baltimore, Md. : 1950) 1999, 162 (11), 6658\u201362.","DOI":"10.4049\/jimmunol.162.11.6658"},{"issue":"5","key":"887_CR122","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, ReiseSousa C. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022\u201337.","journal-title":"Cell"},{"issue":"9","key":"887_CR123","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025\u201336.","journal-title":"Nat Immunol"},{"issue":"7","key":"887_CR124","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","volume":"172","author":"A Fuchs","year":"2004","unstructured":"Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. Cutting edge: CD96 (Tactile) Promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol. 2004;172(7):3994\u20138.","journal-title":"J Immunol"},{"issue":"5","key":"887_CR125","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ni.2850","volume":"15","author":"CJ Chan","year":"2014","unstructured":"Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15(5):431\u20138.","journal-title":"Nat Immunol"},{"issue":"4","key":"887_CR126","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-15-0944","volume":"6","author":"SJ Blake","year":"2016","unstructured":"Blake SJ, Stannard K, Liu J, Allen S, Yong MCR, Mittal D, Aguilera AR, Miles JJ, Lutzky VP, de Andrade LF, Martinet L, Colonna M, Takeda K, Khnel F, Gurlevik E, Bernhardt G, Teng MWL, Smyth MJ. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 2016;6(4):446\u201359.","journal-title":"Cancer Discov"},{"issue":"3","key":"887_CR127","volume":"10","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang C, Qiu J, Qu X, Peng J, Lu C, Zhang M, Zhang M, Qi X, Li G, Hua K. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer. J Immunother Cancer. 2022;10(3): e003667.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"887_CR128","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molimm.2004.07.031","volume":"42","author":"F Borrego","year":"2005","unstructured":"Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE. The cell biology of the human natural killer cell CD94\/NKG2A inhibitory receptor. Mol Immunol. 2005;42(4):485\u20138.","journal-title":"Mol Immunol"},{"issue":"7","key":"887_CR129","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr","year":"2018","unstructured":"Andr P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Blry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. Anti-NKG2A mAb Is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell. 2018;175(7):1731-1743.e13.","journal-title":"Cell"},{"issue":"5","key":"887_CR130","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","volume":"129","author":"T Kamiya","year":"2019","unstructured":"Kamiya T, Seow SV, Wong D, Robinson M, Campana D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Investig. 2019;129(5):2094\u2013106.","journal-title":"J Clin Investig"},{"issue":"1","key":"887_CR131","doi-asserted-by":"crossref","first-page":"2046931","DOI":"10.1080\/2162402X.2022.2046931","volume":"11","author":"K Ducoin","year":"2022","unstructured":"Ducoin K, Oger R, Bilonda Mutala L, Deleine C, Jouand N, Desfranois J, Podevin J, Duchalais E, Cruard J, Benlalam H, Labarrire N, Bossard C, Jarry A, Gervois-Segain N. Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. OncoImmunology. 2022;11(1):2046931.","journal-title":"OncoImmunology"},{"issue":"2","key":"887_CR132","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.it.2017.10.002","volume":"39","author":"ML Bookstaver","year":"2018","unstructured":"Bookstaver ML, Tsai SJ, Bromberg JS, Jewell CM. Improving vaccine and immunotherapy design using biomaterials. Trends Immunol. 2018;39(2):135\u201350.","journal-title":"Trends Immunol"},{"key":"887_CR133","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2017.01668","volume":"8","author":"DC Wraith","year":"2017","unstructured":"Wraith DC. The future of immunotherapy: a 20-year perspective. Front Immunol. 2017;8:1668.","journal-title":"Front Immunol"},{"issue":"2","key":"887_CR134","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205\u201314.","journal-title":"Cell"},{"issue":"3","key":"887_CR135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/imm.12976","volume":"155","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Kitamura T. Macrophage targeting: opening new possibilities for cancer immunotherapy. Immunology. 2018;155(3):285\u201393.","journal-title":"Immunology"},{"issue":"4","key":"887_CR136","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"3","key":"887_CR137","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143\u201358.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"887_CR138","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, Diehn M, West RB, Plevritis SK, Alizadeh AA. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"1","key":"887_CR139","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39\u201351.","journal-title":"Cell"},{"issue":"12","key":"887_CR140","doi-asserted-by":"crossref","first-page":"50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Liu L, Gong C, Shi H, Zeng Y, Wang X, Zhao Y, Wei Y. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE. 2012;7(12):50946.","journal-title":"PLoS ONE"},{"issue":"1","key":"887_CR141","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Shelley Hwang E, Jirstrm K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54\u201367.","journal-title":"Cancer Discov"},{"issue":"7","key":"887_CR142","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"887_CR143","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1158\/1538-7445.AM2017-5655","volume":"77","author":"C Janson","year":"2017","unstructured":"Janson C, Jung H, Ertl L, Liu S, Dang T, Zeng Y, Krasinski A, McMahon J, Zhang P, Charo I, Singh R, Schall TJ. Inhibition of CCR2 potentiates checkpoint inhibitor immunotherapy in murine model of pancreatic cancer. Can Res. 2017;77:5655\u20135655.","journal-title":"Can Res"},{"issue":"7","key":"887_CR144","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.20141836","volume":"212","author":"T Kitamura","year":"2015","unstructured":"Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, Kato Y, Li J, Pollard JW. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 2015;212(7):1043\u201359.","journal-title":"J Exp Med"},{"issue":"7355","key":"887_CR145","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u20135.","journal-title":"Nature"},{"issue":"6","key":"887_CR146","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, DeVisser KE, Italiano A, LeTourneau C, Delord JP, Levitsky H, Blay JY, Rttinger D. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846\u201359.","journal-title":"Cancer Cell"},{"issue":"9","key":"887_CR147","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1039\/c6ib00105j","volume":"8","author":"TD Smith","year":"2016","unstructured":"Smith TD, Tse MJ, Read EL, Liu WF. Regulation of macrophage polarization and plasticity by complex activation signals. Integr Biol (UK). 2016;8(9):946\u201355.","journal-title":"Integr Biol (UK)"},{"key":"887_CR148","first-page":"120","volume":"8","author":"YH Zhang","year":"2017","unstructured":"Zhang YH, He M, Wang Y, Liao AH. Modulators of the balance between M1 and M2 macrophages during pregnancy. Front Immunol. 2017;8:120.","journal-title":"Front Immunol"},{"key":"887_CR149","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.omtn.2021.12.036","volume":"27","author":"H Qian","year":"2022","unstructured":"Qian H, Zhou T, Fu Y, Guo M, Yang W, Zhang D, Fang W, Yao M, Shi H, Chai C, Cheng W, Ding S, Chen T. Self-assembled tetrahedral framework nucleic acid mediates tumor-associated macrophage reprogramming and restores antitumor immunity. Mol Ther Nucl Acids. 2022;27:763\u201373.","journal-title":"Mol Ther Nucl Acids"},{"key":"887_CR150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fimmu.2017.00267","volume":"8","author":"M Irving","year":"2017","unstructured":"Irving M, de Silly RV, Scholten K, Dilek N, Coukos G. Engineering chimeric antigen receptor T-cells for racing in solid tumors: don\u2019t forget the fuel. Front Immunol. 2017;8:267.","journal-title":"Front Immunol"},{"issue":"6382","key":"887_CR151","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"13","key":"887_CR152","doi-asserted-by":"crossref","first-page":"11310","DOI":"10.18632\/oncotarget.3597","volume":"6","author":"ANH Khan","year":"2015","unstructured":"Khan ANH, Kolomeyevskaya N, Singel KL, Grimm MJ, Moysich KB, Daudi S, Grzankowski KS, Lele S, Ylagan L, Webster GA, Abrams SI, Odunsi K, Segal BH. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget. 2015;6(13):11310\u201326.","journal-title":"Oncotarget"},{"issue":"3","key":"887_CR153","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00262-002-0356-5","volume":"52","author":"JEA Portielje","year":"2003","unstructured":"Portielje JEA, Gratama JW, Van Ojik HH, Stoter G, Kruit WHJ. IL-12: A promising adjuvant for cancer vaccination. Cancer Immunol Immunother. 2003;52(3):133\u201344.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"887_CR154","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/cmi.2015.42","volume":"13","author":"T Krneta","year":"2016","unstructured":"Krneta T, Gillgrass A, Chew M, Ashkar AA. The breast tumor microenvironment alters the phenotype and function of natural killer cells. Cell Mol Immunol. 2016;13(5):628\u201339.","journal-title":"Cell Mol Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00887-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-022-00887-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00887-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T19:09:27Z","timestamp":1727982567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-022-00887-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":154,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s10238-022-00887-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}